Golcap Resources Corp.
28.7.2021 23:35:30 CEST | ACCESS Newswire | Press release
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES
VANCOUVER, BC / ACCESSWIRE / July 28, 2021 / Golcap Resources Corp. (CSE:GCP)(OTC PINK:GCRCF) (the "Company" or "Golcap") is pleased to announce the closing of a non-brokered private placement of 10,000,000 units (the "Units") at a price of $0.06 per Unit, for gross proceeds of $600,000 (the "Offering").
Each Unit consisted of one common share (a "Common Share") of the Company and one common share purchase warrant (a "Warrant") exercisable into one Common Share of the Company at a price of $0.075 per Warrant for a period of 60 months from the closing date of the Offering.
All securities to be issued pursuant to the Offering will be subject to a statutory hold period of four months and a day from issuance under applicable Canadian securities law. The proceeds of the Offering are planned to be used for exploration and general working capital purposes.
On closing of the Offering, Crest Resources Inc. ("Crest") (CSE: CRES) acquired 6,300,000 Units of the Company. As a result, it is deemed to own 22.58% of the outstanding shares of the Company and is a "control person" as that term is defined under securities legislation. Assuming the exercise of 6,300,000 warrants acquired with the Units, Crest would own 12,600,000 common shares or 36.84% of the outstanding shares of the Company.
This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the shares in the United States. The shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
On behalf of the Board of Directors
Gordon Lam
President and Chief Executive Officer
Email: info@golcapresources.com
Telephone: (604) 675-2011
Website: www.golcapresources.com
The information in this news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward looking statements. Forward-looking statements in this news release include, but are not limited to, the Company's proposed use of the proceeds of its offering. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Company believes that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward looking statements will prove to be correct. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward looking statements or otherwise.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: Golcap Resources Corp.
View source version on accesswire.com:
https://www.accesswire.com/657520/Golcap-Closes-Private-Placement
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
GoodData Kicks Off 2026 with MCP Server Launch and Major Enterprise Wins15.4.2026 12:00:00 CEST | Press release
Financial services wins and three platform launches signal accelerating enterprise demand for agentic analytics. SAN FRANCISCO, CA / ACCESS Newswire / April 15, 2026 / GoodData, a leading AI-native decision intelligence platform, today announced strong Q1 2026 results driven by the launch of its MCP Server for agentic analytics, significant new contracts in global financial services, and continued expansion into new markets. The quarter built on a record-breaking 2025, reinforcing GoodData's position as the platform enterprises trust to move AI from pilot to production. Continued growth across enterprise and financial services GoodData's commercial momentum remained strong throughout Q1, with notable wins across the enterprise and financial sectors. The company secured a new three-year contract with one of the world's largest asset managers, and a key long-term customer in global payments renewed for three years while expanding its enterprise license. "Our Q1 results demonstrate that t
GoodData Kicks Off 2026 with MCP Server Launch and Major Enterprise Wins15.4.2026 12:00:00 CEST | Press release
Financial services wins and three platform launches signal accelerating enterprise demand for agentic analytics. SAN FRANCISCO, CA / ACCESS Newswire / April 15, 2026 / GoodData, a leading AI-native decision intelligence platform, today announced strong Q1 2026 results driven by the launch of its MCP Server for agentic analytics, significant new contracts in global financial services, and continued expansion into new markets. The quarter built on a record-breaking 2025, reinforcing GoodData's position as the platform enterprises trust to move AI from pilot to production. Continued growth across enterprise and financial services GoodData's commercial momentum remained strong throughout Q1, with notable wins across the enterprise and financial sectors. The company secured a new three-year contract with one of the world's largest asset managers, and a key long-term customer in global payments renewed for three years while expanding its enterprise license. "Our Q1 results demonstrate that t
OBI Pharma Announces Ten Poster Presentations at the AACR 2026 Annual Meeting for GlycOBI(R) Glycan-based Site-Specific Antibody-Drug Conjugates (ADCs): Mono and Bi-Specific (inc. Dual payload) and Obrion(TM) ADC enabling technologies15.4.2026 10:40:00 CEST | Press release
Poster Presentations featuring the latest advancements on anti-TROP2 (OBI 902) and Nectin-4 (OBI 904) ADCs, anti-TROP2/HER2 BsADC (OBI 201), anti-cMET/HER3Bs-Dual Payload ADC (OBI 221),and OBI's novel Obrion ™ ADC enabling technologies(GlycOBI ® and GlycOBI DUO ®). TAIPEI, TW / ACCESS Newswire / April 15, 2026 / OBI Pharma, Inc. (TPEx:4174.TWO) today announced its presence at AACR 2026, highlighted by ten poster presentations, showcasing the transformative potential of the GlycOBI® platform. Conventional ADCs often face limitations due to random conjugation, resulting in heterogeneous Drug-to-Antibody Ratios (DAR), suboptimal stability, and narrow therapeutic windows. In contrast, the OBI site-specific glycan-based technology enables a highly homogeneous DAR, translating into improved PK/PD profiles, and reduced off-target toxicity, as demonstrated by OBI's lead programs, OBI-902 and OBI-904. We are further advancing precision oncology through our next-generation bispecific (OBI-201) a
OBI Pharma Announces Ten Poster Presentations at the AACR 2026 Annual Meeting for GlycOBI(R) Glycan-based Site-Specific Antibody-Drug Conjugates (ADCs): Mono and Bi-Specific (inc. Dual payload) and Obrion(TM) ADC enabling technologies15.4.2026 10:40:00 CEST | Press release
Poster Presentations featuring the latest advancements on anti-TROP2 (OBI 902) and Nectin-4 (OBI 904) ADCs, anti-TROP2/HER2 BsADC (OBI 201), anti-cMET/HER3Bs-Dual Payload ADC (OBI 221),and OBI's novel Obrion ™ ADC enabling technologies(GlycOBI ® and GlycOBI DUO ®). TAIPEI, TW / ACCESS Newswire / April 15, 2026 / OBI Pharma, Inc. (TPEx:4174.TWO) today announced its presence at AACR 2026, highlighted by ten poster presentations, showcasing the transformative potential of the GlycOBI® platform. Conventional ADCs often face limitations due to random conjugation, resulting in heterogeneous Drug-to-Antibody Ratios (DAR), suboptimal stability, and narrow therapeutic windows. In contrast, the OBI site-specific glycan-based technology enables a highly homogeneous DAR, translating into improved PK/PD profiles, and reduced off-target toxicity, as demonstrated by OBI's lead programs, OBI-902 and OBI-904. We are further advancing precision oncology through our next-generation bispecific (OBI-201) a
IDC Defines the Next Era of Technology Intelligence with the Introduction of IDC Quanta(TM) at Directions 20268.4.2026 17:15:00 CEST | Press release
New AI-powered platform establishes an embedded intelligence layer for the AI economy, delivering decision-grade insight BOSTON, MA / ACCESS Newswire / April 8, 2026 / IDC today opened IDC Directions 2026, its flagship client event, bringing together technology leaders, analysts, and industry experts to examine the forces reshaping the global technology market and to introduce a major evolution in how technology intelligence is delivered. At the center of this year's event is IDC Quanta™, a new AI-powered platform that establishes what IDC defines as the technology intelligence layer for the AI economy. As artificial intelligence accelerates the pace of business and compresses decision cycles, IDC is redefining its role from a destination for research and data to an embedded intelligence capability that delivers trusted insight directly into the workflows where decisions are made. "AI is compressing time across the entire technology market, and that breaks the traditional research mode
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
